Premium
High allele loss rates at I7q I2‐q2I in breast and ovarian tumors from BRCAI ‐linked families
Author(s) -
Cornelis R. S.,
Neuhausen S. L.,
Johansson O.,
Arason A.,
Kelsell D.,
Ponder B. A. J.,
Tonin P.,
Hamann U.,
Lindblom A.,
Lalle P.,
Longy M.,
Olàh E.,
Scherneck S.,
Big Y. J.,
Sobol H.,
ChangClaude J.,
Larsson C.,
Spurr N.,
Borg A.,
Barkardottir R. B.,
Narod S.,
Devilee P.
Publication year - 1995
Publication title -
genes, chromosomes and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.754
H-Index - 119
eISSN - 1098-2264
pISSN - 1045-2257
DOI - 10.1002/gcc.2870130310
Subject(s) - loss of heterozygosity , allele , locus (genetics) , biology , ovarian cancer , genetics , haplotype , genotype , breast cancer , cancer research , cancer , gene
Loss of heterozygosity (LOH) was evaluated in 174 breast and ovarian tumors derived from 94 families with at least 3 first‐degree relatives affected with either of these cancers. By linkage analysis 26 families were identified as having a high posterior probability of being due to BRCAI (the breadovarian cancer susceptibility locus on 17q 12–21) with lod scores varying from 0.5 1 to 9.49. Tumor genotypes were determined at at least 2 constitutionally heterozygous markers flanking BRCA I in a total of 58 tumors from these families. These tumors were derived from 52 patients, the BRCAI mutation carrier status of which was evidenced by DNA sequencing in 20, and inferred by reconstructing haplotypes in the remainder. LOH was detected in 50 (86%) tumors. and invariably involved the wild‐type allele. Where informative, this allele was of paternal origin in 33 cases and of maternal origin in I0 cases. These results strongly suggest that BRCA I is a tumor suppressor gene and that LOH is greatly favored to fully inactivate it. © 1995 Wiley‐Liss, Inc.